Olaparib AZD-2281 CAS 763113-22-0 Maʻemaʻe ≥99.0% API Factory
Maʻemaʻe Kiʻekiʻe, Hana Kūʻai
ʻO Olaparib a me nā mea pili e pili ana:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)ʻakika benzoic CAS 763114-26-7
1-(Cyclopropylcarbonyl)piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Inoa Kimia | ʻOlaparib |
| Nā huaʻōlelo like | AZD-2281;KU0059436;Lynparza;4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin |
| Helu CAS | 763113-22-0 |
| Helu CAT | RF-API103 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C24H23FN4O3 |
| Kaumaha Molecular | 434.46 |
| Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia ma DMSO |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Keʻokeʻo a hiki i ka pauda keʻokeʻo |
| ʻIke ʻia e 1H NMR | E hoʻokō me ka hoʻolālā |
| LC-MS | E hoʻokō me ka hoʻolālā |
| Maʻemaʻe / Kaʻina Hanana | ≥99.0% (na LC-MS) |
| Māmā (KF) | ≤0.50% |
| Hoʻokahi haumia | ≤0.50% |
| Huina paumaele | ≤1.0% |
| Nā Metala Kaumaha (e like me Pb) | ≤20ppm |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | API;PARP mea pale |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai.
ʻO Olaparib (CAS: 763113-22-0), kahi mea hoʻoweliweli PARP ikaika loa a koho.I ka lā 19 o Kekemapa, 2014, ua ʻae ka FDA i ka lāʻau lapaʻau anti-cancer Olaparib (Lynparza) no ka monotherapy i nā poʻe maʻi o ka maʻi maʻi ovarian kiʻekiʻe i loaʻa ma kahi o 3 mau pōʻai o ka chemotherapy a i ʻole nā mea maʻi i manaʻo ʻia he hoʻololi BRCA.I ka manawa like, ua ʻae ʻo FDA i ka nui a me ka hoʻokaʻawale ʻana o nā pahu diagnostic no ka ʻike ʻana i nā hoʻololi i BRCA1 a me BRCA2, BRACAnalysis CDx.ʻO Olaparib ka lāʻau lapaʻau PARP mua i ʻae ʻia e FDA.Ma Pepeluali 2, 2015, ua ʻae pū ka European Union Food and Drug Administration (EMA) iā Olaparib e komo i ka mākeke ma nā ʻāina 28 o ʻEulopa me Iceland, Liechtenstein a me Norewai.Akā ʻokoʻa iki nā hōʻailona o EMA a me FDA;ʻO ka mea mua no nā hihia hoʻololi o ka BRCA gene, a no ka mālama mālama ʻana no nā poʻe maʻi o ka epithelial ovarian cancer i loaʻa mua i ka platinum-containing chemotherapy drugs a hōʻike i ka pane a hiki ke hoʻi hou.
